# US 2025/0017913 A1 · Local topical formulation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017913 A1
- Document ID: US20250017913A1
- Status: Published application
- Kind: A1
- Application number: 18/682,329
- Filed: 2022-08-18
- Published: 2025-01-16
- Earliest claimed: 2021-08-19
- Assignees: Zhuhai United Laboratories Co., Ltd.
- Applicants: Zhuhai United Laboratories Co., Ltd.
- Inventors: Meiyue SHEN; Liwei MU; Tingting YU; Yujun HE; Chong SU; Peng GAO; Zheng WANG; Degang WANG
- Web page: https://patentgrep.com/patent/US20250017913A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present application relates to the field of pharmaceutical preparations and relates to [1,2,4]triazolo [1,5-a]pyridine compounds and their isomers or pharmaceutically acceptable salts or their crystal forms, as well as local topical preparations and their applications in skin diseases. Specifically, it relates to a local topical formulations of compound (S)—N-(5-(2-(2,2-difluorocyclopropanecarbonyl)-2-nitrospiro[3.5]non-7-yl)-[1,2,4-triazole[1,5-a]pyridine-2-yl) cyclopropaneformamide and its isomers or pharmaceutically acceptable salts or crystal forms, and their applications in skin diseases. The preferred skin diseases include psoriasis, atopic dermatitis, vitiligo, lupus erythematosus, alopecia areata, eczema, contact dermatitis, urticaria, pompholyxs, dermatomyositis, scleroderma, acne, and seborrheic dermatitis.

## Claims

### Claim 1

A topical preparation containing a JAK inhibitor, wherein the local topical preparation comprises the JAK inhibitor, a matrix and an additive agent, wherein the JAK inhibitor comprises a compound of formula (I), an isomer thereof, pharmaceutically acceptable salts thereof, or crystal form A thereof:
where,
E1 and E2 are independently selected from a group consisting of single bond, —CH2— or —(CH2)2—, respectively;
L1 is selected from single bond, —(CH2)g—, -c(═O)— or -c(═O)—(CH2)—h;
m is 1 or 2;
n is 1 or 2;
g is 1, 2 or 3;
h is 1, 2 or 3;
R1 is selected from H, CN, C1-6 alkyl or 3-6-mnembered cycloalkyl, wherein the C1-6 alkyl and 3-6-membered cycloalkyl are optionally substituted by 1, 2 or 3 Ra;
R2 is selected from H, F, Cl, Br, I or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1,2 or 3 R;
R3, R4 and R5 are in dependently selected from H, F, Cl, Br, I or C1-3 alkyl respectively, wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 Re;
R6, R7 and R8 are independently selected from H, F, Cl, Br, I or C1-3 alkyl, respectively, wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 Rd;
Each Ra is independently selected from H, F, Cl, Br, I, CN or C1-3 alkyl, respectively, wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 R;
Each Rb is independently selected from F, Cl, Br or I;
Each Rc is independently selected from F, Cl, Br or I;
Each Rd is independently selected from F, Cl, Br or I; and
Each R is independently selected from F, Cl, Br or I.

### Claim 2 (depends on 1)

The topical preparation according to claim 1, wherein each Ra is independently selected from H, F, Cl, Br, I, or CN.

### Claim 3 (depends on 1)

The topical preparation according to claim 1, wherein R1 is selected from H, CN, C1-3 alkyl or 3-5-membered cycloalkyl, wherein the C1-3 alkyl and 3-5-membered cycloalkyl are optionally substituted by 1, 2, or 3 Ra.

### Claim 4 (depends on 3)

The topical preparation according to claim 3, wherein R1 is selected from H, CN, CH3,
wherein CH3,
is optionally substituted by 1, 2, or 3 Ra.

### Claim 5 (depends on 4)

The topical preparation according to claim 4, wherein R1 is selected from H, CN, CF3, CHF2,

### Claim 6 (depends on 1)

The topical preparation according to claim 1, wherein R2 is selected from H, F, Cl, Br, or I.

### Claim 7 (depends on 1)

The topical preparation according to claim 1, wherein R3, R4, and R5 are independently selected from H, F, Cl, Br, or I.

### Claim 8 (depends on 1)

The topical preparation according to claim 1, wherein R6, R7, and R8 are independently selected from H, F, Cl, Br, or I.

### Claim 9 (depends on 1)

The topical preparation according to claim 1, wherein L1 is selected from a single bond, —CH2—, —(CH2)2—, —C(═O)— or —C(═O)—(CH2)—.

### Claim 10 (depends on 1)

The topical preparation according to claim 1, wherein the structural unit
is selected from

### Claim 11 (depends on 1)

The topical preparation according to claim 1, wherein the structural unit
is selected from

### Claim 12 (depends on 1)

The topical preparation according to claim 1, wherein the structural unit
is selected from

### Claim 13 (depends on 1)

The topical preparation according to claim 1, wherein the compound of formula (I), isomers thereof, or pharmaceutically acceptable salts thereof is selected from

### Claim 14 (depends on 13)

The topical preparation according to claim 13, wherein the compound of formula (I), isomers thereof, or pharmaceutically acceptable salts thereof is

### Claim 15

A topical preparation containing a JAK inhibitor, wherein the JAK inhibitor comprises the following compounds, their isomers, or pharmaceutically acceptable salts thereof

### Claim 16 (depends on 15)

The topical preparation according to claim 15, wherein the compound of formula (I), isomers thereof, or pharmaceutically acceptable salts thereof is selected from

### Claim 17 (depends on 1)

The topical preparation according to claim 1, wherein the matrix is selected from an oil soluble matrix, a water-soluble matrix, or a combination of two or more of them.

### Claim 18 (depends on 17)

The topical formulation according to claim 17, wherein the oil soluble matrix is selected from oil substances, hydrocarbons, lipids, synthetic (semi synthetic) oil substances, or a combination of two or more of them-,
wherein the oil substances are selected from porcine fat, sheep fat, cow fat, sesame oil, sesame oil, cottonseed oil, soybean oil, peanut oil, olive oil, vegetable oil, hydrogenated vegetable oil, or a combination of two or more of them;
wherein the hydrocarbons are selected from white vaseline, yellow vaseline, liquid paraffin, white wax, paraffin, microcrystalline paraffin, ground wax, Sasol paraffin, or a combination of two or more of them;
wherein the lipids are selected from lanolin, beeswax, whale wax, or a combination of two or more of them;
wherein the hydrocarbons are selected from white vaseline, yellow vaseline, liquid paraffin, white wax, paraffin, microcrystalline paraffin, ground wax, Sasol paraffin, or a combination of two or more of them;
herein the oil substances are selected from lanolin, beeswax, whale wax, or a combination of two or more of them; or
wherein the synthesized (semi synthetic) oil substances are selected from squalane, lanolin derivatives, lanolin alcohol, acetylated lanolin, polyoxyethylene lanolin, hydrogenated lanolin, silicone, glyceryl behenate, palmitic acid, stearic acid, isostearic acid, octadecanol, cetanol, stearanol, or a combination of two or more of them.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 17)

The topical preparation according to claim 17, wherein the water-soluble matrix is selected from polyethylene glycol 3350 (PEG 3350), polyethylene glycol 400 (PEG 400), cellulose derivatives, or two or more combinations thereof.

### Claim 26 (depends on 1)

The topical preparation according to claim 1, wherein the additive comprises one or more antioxidants.

### Claim 27 (depends on 26)

The topical preparation according to claim 26, wherein the antioxidant is selected from sodium bisulfite, sodium metabisulfite, sodium thiosulfate, sodium sulfite, vitamin C, cysteine, methionine, tert butyl p-hydroxyanisole, dibutylhydroxytoluene, propyl gallate, vitamin E, edetic acid (EDTA), citric acid, tartaric acid, or a combination of two or more of them.

### Claim 28 (depends on 1)

The topical preparation according to claim 1, wherein the additive comprises one or more preservatives.

### Claim 29 (depends on 28)

The topical preparation according to claim 28, wherein the preservative is selected from trichloro tert butanol, benzoic acid, sorbic acid, phenol, cresol, hydroxybenzyl methyl ester, hydroxybenzyl ethyl ester, benzalkonium bromide, benzalkonium chloride, or a combination of two or more of them.

### Claim 30 (depends on 1)

The topical preparation according to claim 1, wherein the additive comprises one or more moisturizing agents.

### Claim 31 (depends on 30)

The topical preparation according to claim 30, wherein the moisturizing agent is selected from glycerol, propylene glycol, sorbitol, or a combination of two or more of them.

### Claim 32 (depends on 1)

The topical preparation according to claim 1, wherein the additive comprises one or more solubilizers.

### Claim 33 (depends on 32)

The topical preparation according to claim 32, wherein the solubilizer is selected from monoglyceryl linoleic acid, diethylene glycol monoethyl ether, polyglycerol fatty acid ester, or a combination of two or more of them.

### Claim 34 (depends on 1)

The topical preparation according to claim 1, wherein the local topical preparation comprises the JAK inhibitor, one or more matrices, one or more additive agents, wherein the JAK inhibitor is a compound of structural formula (II), formula (III), formula (IV), formula (V), or formula (VI) and its isomer, or a pharmaceutically acceptable salt thereof, or one of its crystal forms:

### Claim 35 (depends on 34)

The topical preparation according to claim 34, wherein a content of JAK inhibitors is 0.01% to 10%, preferably 0.02% to 9%, further preferably 0.03% to 8%, of a total weight of the local topical preparation.

### Claim 36 (depends on 34)

The topical preparation according to claim 34, wherein one or more matrices are selected from an oil soluble matrix,
wherein the oil soluble matrix is selected from white vaseline, white wax, liquid paraffin, paraffin, Sasol paraffin, microcrystalline paraffin, or a combination of two or more of them.

### Claim 37

(canceled)

### Claim 38 (depends on 37)

The topical preparation according to claim 37, wherein the content of white vaseline is 45% to 96%, preferably 50% to 95%, more preferably 53% to 94%, further preferably 55% to 93%, further preferably 56% to 92%, of the total weight of the topical preparation;
wherein a content of white wax is 0.5% to 10%, preferably 1% to 9%, more preferably 2% to 8%, further preferably 3% to 6%, more preferably 4% to 5% of the total weight of the local topical preparation;
wherein the content of liquid paraffin is 0.2% to 50%, preferably 1% to 40%, more preferably 1.5% to 30%, further preferably 2% to 20%, more preferably 2.5% to 15% of the total weight of the local topical preparation;
wherein a content of paraffin is 1% to 8%, preferably 2% to 7% of the total weight of the topical preparation;
wherein the content of Sasol paraffin is 1% to 10%, preferably 1.5% to 9%, more preferably 2% to 8%, further preferably 2.5% to 7%, more preferably 3% to 6% of the total weight of the local topical preparation; or
wherein the content of microcrystalline paraffin is 2% to 50%, preferably 4% to 45%, more preferably 5% to 40%, further preferably 7% to 35%, more preferably 9% to 30% of the total weight of the local topical preparation.

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 34)

The topical preparation according to claim 34, wherein one or more matrices are selected from water-soluble matrices PEG 400, PEG 3350, or a combination thereof.

### Claim 45 (depends on 44)

The topical preparation according to claim 44, wherein the content of PEG 400 is 60% to 90%, preferably 65% to 85%, most preferably 66%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 78.4%, 78.5%, 79%, 80%, 82%, or 84% of the total weight of the local topical preparation; or
wherein the content of PEG 3350 is 10% to 40%, preferably 15% to 30% of the total weight of the topical preparation.

### Claim 46

(canceled)

### Claim 47 (depends on 44)

The topical preparation according to claim 44, wherein the content ratio of PEG 400 and PEG 3350 is 1:8-1:1, preferably 1:6-1:2, more preferably 1:5-1:3, and most preferably 1:4.

### Claim 48 (depends on 34)

The topical preparation according to claim 34, wherein the additive agent comprises octadecanol, stearic acid, diethylene glycol monoethyl ether, polyglycerol fatty acid ester, monoglyceryl linoleic acid, glyceryl behenate, glyceryl monostearate, or a combination of two or more of them.

### Claim 49 (depends on 48)

The topical preparation according to claim 48, wherein the content of octadecanol is 1% to 10%, preferably 2% to 9%, more preferably 3% to 8%, further preferably 4% to 7% of the total weight of the topical preparation;
wherein the content of stearic acid is 1% to 10%, preferably 1.5% to 9%, more preferably 2% to 8%, further preferably 2.5% to 7%, further preferably 3% to 6% of the total weight of the topical preparation;
wherein the content of diethylene glycol monoethyl ether is 1% to 10%, preferably 1.5% to 9%, more preferably 2% to 8%, further preferably 2.5% to 7%, further preferably 3% to 6% of the total weight of the topical preparation;
wherein the content of the polyglycerol fatty acid ester is 1% to 10%, preferably 1.5% to 9%, more preferably 2% to 8%, further preferably 2.5% to 7%, further preferably 3% to 6% of the total weight of the local topical preparation;
wherein the content of monolinoleic acid glyceride is 1% to 10%, preferably 1.5% to 9%, more preferably 2% to 8%, further preferably 2.5% to 7%, further preferably 3% to 6% of the total weight of the local topical preparation;
wherein the content of glyceryl behenate is 1% to 10%, preferably 2% to 9%, more preferably 3% to 8%, most preferably 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, or 6.5% of the total weight of the local topical preparation; or
wherein the content of monostearic acid glycerol is 1% to 10%, preferably 2% to 9%, more preferably 3% to 8% of the total weight of the local topical preparation.

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56 (depends on 1)

The method for preparing a topical preparation according to claim 1, wherein a preparation method is selected from grinding method or melting method, preferably the melting method.

### Claim 57 (depends on 1)

The topical preparation according to claim 1, wherein the preparation is an ointment, cream, paste, gel, film, paste or patch.

### Claim 58 (depends on 1)

A method for treating skin diseases, preferably psoriasis, atopic dermatitis, vitiligo, lupus erythematosus, alopecia areata, eczema, contact dermatitis, urticaria, pompholyx, dermatomyositis, scleroderma, acne, and seborrheic dermatitis, comprising applying the topical preparation of claim 1 to a local area of a subject requiring such treatment.
